A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Phase 1
103
about 3.5 years
18+
1 site in TX
About this study
Researchers are testing a treatment called BGC515 in adults with advanced solid tumors. The goal is to see if the treatment is safe and how it works in the body, as well as whether it shows any early signs of effectiveness. The trial will last for about 1282 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BGC515
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Dose-limiting toxicities (DLTs), Incidence of adverse events (AEs) and serious adverse events (SAEs)., Objective response rate (ORR), Progress-free survival(PFS)
Secondary: Half-life (t1/2)., Peak concentration (Cmax)., Time to peak concentration (Tmax).
Oncology